Medication may show faster results
In contrast to leading competitors, Amino Asylum fails to provide quality assurance documentation on every single product
4-( N -( S -glutathionylacetyl)amino)phenylarsonous acid is a prospective cancer drug and has just completed a phase I dose escalation study in patients with solid tumors refractory to standard therapy ( 4-( N -( S -glutathionylacetyl)amino)phenylarsonous acid consists of a phenylarsenoxide moiety attached by an N -acetyl linker to the cysteine thiol of reduced GSH ( Figure 3 )
However, the same process may protect tumor cells and possibly minimize the effect of cancer therapies (11)
[33] Ferreira, B., Mendes, F., Osorio, N., Caseiro, A., Gabriel, A
An approved drug label with formal contraindications does not yet exist for CagriSema